We conducted an observational, prospective, monocentric study. Patients attended our center for two visits, at baseline (T0) and after one year from the first visit (T1). All participants started biologic therapy with benralizumab immediately after T0.
For every patient detailed clinical data were recorded such as general characteristics, comorbidities, allergic status, smoking habit, inhaled therapy, and number of previous sinus surgery.
At both T0 and T1, all subjects performed the following investigations: blood eosinophil count, total serum Ig-E, respiratory function assessment with pre-post bronchodilator spirometry, exhaled nitric oxide (FeNO) test, asthma symptoms assessment with Asthma Control Test (ACT), OCS therapy with daily dosage, number of previous year exacerbations, ENT examination with nasal endoscopy for obtaining Nasal Polyp Score (NPS), nasal cytologic sampling, CRswNP symptoms assessment with Sino-Nasal Outcome Test 22 (SNOT 22). In addition, the need for sinus surgery was assessed for each patient at T1.
For every patient detailed clinical data were recorded such as general characteristics, comorbidities, allergic status, smoking habit, inhaled therapy, and number of previous sinus surgery.
At both T0 and T1, all subjects performed the following investigations: blood eosinophil count, total serum Ig-E, respiratory function assessment with pre-post bronchodilator spirometry, exhaled nitric oxide (FeNO) test, asthma symptoms assessment with Asthma Control Test (ACT), OCS therapy with daily dosage, number of previous year exacerbations, ENT examination with nasal endoscopy for obtaining Nasal Polyp Score (NPS), nasal cytologic sampling, CRswNP symptoms assessment with Sino-Nasal Outcome Test 22 (SNOT 22). In addition, the need for sinus surgery was assessed for each patient at T1.
